AUA Regional Meetings

Videos

“I think the take home message of this study is that there's work to do, and that our efforts in diversity, equity, and inclusion extends broadly beyond simply ensuring that we have the workforce to treat our diverse population, or that urologists are thinking critically and responsibly about the needs of our patients,” says Kevin Koo, MD, MPH.

Dr. Koo on diversity, equity, and inclusion in urology drug trials

“One thing that from the very beginning we talked about is how can we push this forward? How can we think outside the box and take this to the next level to make an impact for our patients?” says Katie Murray, DO, MS.

Prostatic artery embolization as a collaboration between urology and interventional radiology

Articles

Two studies shared at the 2022 Annual Meeting of the South Central Section of the AUA highlighted onabotulinumtoxinA and sacral nerve stimulation as alternative treatment options for patients older than 70 years with overactive bladder.

Botox, sacral nerve stimulation highlighted as emerging OAB treatments for elderly patients

“The main finding of the study was that, like…other clinical trial studies in the past, we also found that there was an over representation of non-Hispanic White patients in these trials, and a dramatic under representation of people traditionally and historically underrepresented in clinical trials and in medicine,” says Kevin Koo, MD, MPH.



Study evaluates representation in urology drug trials

“A majority of the patients who were referred who had a catheter pre embolization are now catheter free,” says Kimberly Kocour, MD.

Dr. Kocour and Dr. Murray on embolization of the prostate

“This concept of adding additional therapy early on is ready for primetime,” says Michael S. Cookson, MD, MMHC.

Dr. Cookson on darolutamide data: “An exciting move forward”

“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.

What’s next for Black-tailored prostate cancer risk calculator?

“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.

Early use of darolutamide with ADT and docetaxel shows efficacy in mHSPC

"The biggest advantage of this technique is that because the sound waves are coming from inside and going outwards, it doesn't destroy anything beyond the prostate, at least in theory,” said Michael Koch, MD.

Long-term data support MRI-guided TULSA for localized prostate cancer

“We actually found that our calculator held up pretty well at different risk thresholds, especially when compared to the PCPT in terms of maintaining the same number of missed cancers, but cutting the number of biopsies that were not necessary nearly in half,” says Neil Mistry, MD, MPH.